Business Wire (Thu, 8:01AM)
Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
1,466 people get STJ articles and Market Currents by email alert.
Get email alerts on STJ »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
Business Wire (May 8, 2013)
-
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 30, 2013)
-
-
Business Wire (Apr 17, 2013)
-
Business Wire (Apr 4, 2013)
-
5 Cheap Dividend Stocks Worth InvestigatingMarshall Hargrave • Tue, Mar 26 -
Business Wire (Mar 21, 2013)
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
Boston Scientific Could Benefit From St. Jude Medical's TroublesTrefis • Tue, Nov 27, 2012 -
-
-
Why St. Jude Is Poised To Become A Solid Income StockValuentum • Thu, Sep 20, 2012 -
St. Jude Medical's Weaker Guidance Presents Another OpportunityStephen Simpson • Wed, Jul 18, 2012
-
-
-
-
-
-
St. Jude Medical: Earnings PreviewZacks Investment Research • Wed, Jan 25, 2012
-
Quality, With A Dividend, Now On Sale: St. Jude MedicalK202 • Tue, Jan 10, 2012 -
St. Jude Remains On Our Dividend Growth Watch ListValuentum • Wed, Jan 4, 2012
-
-
St. Jude: Earnings PreviewZacks Investment Research • Wed, Oct 19, 2011
-
-
-
-
5 Cheap Dividend Stocks Worth InvestigatingMarshall Hargrave • Tue, Mar 26
-
-
-
-
-
-
Fortune Could Favor A Bolder TerumoStephen Simpson • Thu, Feb 21
-
-
-
-
-
-
-
-
Checking The Pulse Of Healthcare StocksStock Traders Daily • Tue, Jan 22
-
-
-
St. Jude Medical Inc. - Analyst/Investor DayFri, Feb 3, 2012
-
St. Jude Medical Q2 2010 Earnings Call TranscriptThu, Jul 22, 2010
-
St. Jude Medical Inc. Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
St. Jude Medical Inc. Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
St. Jude Medical Inc., Q3 2009 Earnings Call TranscriptWed, Oct 21, 2009
-
St. Jude Medical, Inc. Q2 2009 Earnings Call TranscriptWed, Jul 22, 2009
-
St. Jude Medical, Inc. Q1 2009 Earnings Call TranscriptWed, Apr 22, 2009 • 1 Comment
-
St. Jude Medical Inc. Q4 2008 Earnings Call TranscriptTue, Jan 27, 2009
-
Business Wire (May 8, 2013)
-
Business Wire (May 3, 2013)
-
Business Wire (May 2, 2013)
-
Business Wire (May 1, 2013)
-
Business Wire (Apr 30, 2013)
-
Business Wire (Apr 17, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 9, 2013)
-
Business Wire (Apr 4, 2013)
-
Business Wire (Mar 21, 2013)
-
Business Wire (Mar 20, 2013)
-
Business Wire (Mar 11, 2013)
-
Business Wire (Feb 27, 2013)
-
at Fox Business (Feb 25, 2013)
STJ vs. ETF Alternatives
Company Description
St. Jude Medical, Inc. develops, manufactures and distributes cardiovascular medical devices for the global cardiac rhythm management, cardiology and cardiac surgery and atrial fibrillation therapy areas and neurostimulation medical devices for the management of chronic pain. Our four operating... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Sunday, August 26, 2012, 4:25 AM Patients are facing costs of thousands of dollars to replace leads that connect St. Jude's (STJ) Riata defibrillators to the heart after the leads were recalled in December. While St. Jude will provide a replacement, patients formally have to pay for travel, hotel and the substitute if the product comes from another company. However, St. Jude has been known to foot the bill when asked. 1 Comment [Healthcare]
- Tuesday, August 21, 2012, 8:33 AM A study of St. Jude Medical's (STJ -0.5%) Durata heart defibrillator finds 52 instances of insulation failures with the leads of the device, including one case that resulted in death. Changes to the product, such as adding more insulation, failed to solve the problems that had led to the recall of a previous model. Comment! [Healthcare]
- Thursday, August 16, 2012, 2:34 PM St. Jude Medical (STJ -3.5%) drops after the FDA orders a review of its Riata defibrillator leads. The agency recommends patients who have defibrillators with Riata leads should have x-rays or other imaging scans to check for abnormalities in the insulation surrounding the lead. STJ recalled the leads back in Nov. 2011; FDA says routine imaging may detect previously unrecognized abnormalities. Comment! [Healthcare, On the Move]
- Wednesday, August 1, 2012, 9:46 AM St. Jude Medical (STJ) declares $0.23/share quarterly dividend, in line with previous. Forward yield 2.44%. For shareholders of record Sep 28. Payable Oct 31. Ex-div date Sep 26. (PR) Comment! [Dividends]
- Wednesday, July 18, 2012, 8:53 AM More on St. Jude Medical (STJ -0.1%) Q2: net profit +1.2% to $244M, helped by reduced costs, although a weakness in the demand for heart-rhythm devices and forex effects weigh on earnings. Cuts FY EPS outlook by $0.04 to $3.40- $3.45 vs. consensus of $3.46. For Q3, forecasts $0.80-$0.82 vs. $0.83. Comment! [Earnings, Healthcare]
- Wednesday, July 18, 2012, 8:00 AM St. Jude Medical (STJ): Q2 EPS of $0.86 misses by $0.01. Revenue of $1.41B (-2.5% Y/Y). (PR) Comment! [Earnings, Healthcare]
- Wednesday, July 18, 2012, 12:05 AM Notable earnings before Wednesday’s open: ABT, APH, ASML, BAC, BK, BLK, BPOP, CHKP, DOV, ERIC, GWW, HON, KCG, NTRS, PNC, STJ, SWK, USB Comment! [Earnings]
- Tuesday, July 17, 2012, 5:30 PM Notable earnings before Wednesday’s open: ABT, APH, ASML, BAC, BK, BLK, BPOP, CHKP, DOV,ERIC, GWW, HON, KCG, NTRS, PNC, STJ, SWK, USB Comment! [Earnings]
- Monday, July 16, 2012, 9:27 AM St. Jude Medical (STJ) says that the erosion of leads for its recalled Riata defibrillator occurred from the inside out most often in cables with larger diameters, the initial findings of a study show. St. Jude faces a class action lawsuit over the leads. Comment! [Healthcare]
- Thursday, June 28, 2012, 11:32 AM The Supreme Court opinion on the Healthcare Act means that medical device makers still face a 2.3% tax on domestic sales starting next year unless they can persuade Congress to repeal it. Shares are sliding: MDT -1.2%, BSX -2.7%, STJ -1%, EW 1.1%, SYK -1.9%, ATRC -4.7%, CYBX -1.6%. 1 Comment [Healthcare, On the Move]
- Monday, June 25, 2012, 2:34 PM Goldman says that St. Jude's (STJ +0.2%) finding that its Durata lead failure was due to external abrasion means initial fears were unfounded and that the performance of the device will support further utilization and not lead to a major negative safety event. The firm continues to rate the shares a Buy. Additionally, Canaccord also reiterates a Buy, recommending investors add to positions. Comment! [Healthcare]
- Monday, June 25, 2012, 11:41 AM St. Jude (STJ +0.2%) bucks a weak tape after saying late Friday it's identified a single Durata defibrillator lead that was damaged due to an external abrasion, but notes the lead did not have the critical flaw of an earlier version of the device that St. Jude no longer sells. Comment! [Healthcare]
- Friday, June 22, 2012, 4:11 PM St. Jude Medical (STJ +2.6%) jumps at the close after a last-minute release of comments on a database report suggesting a single Durata defibrillation lead was damaged by external abrasion - different from the inside-out abrasion seen previously on Riata leads. (previously) Comment! [Healthcare, On the Move]
- Monday, June 18, 2012, 1:10 PM Lazard Capital upgrades St. Jude Medical (STJ +3.2%) to Buy, questioning concerns about a Durata defibrillator cable. A report turned up in an FDA database and was said to be due to a fraying issue, prompting fears that problems with STJ's earlier Riata product may not be isolated. But anyone can file to that database, Lazard says, and the cable wasn't returned to STJ for analysis. 3 Comments [Healthcare, On the Move]
- Thursday, June 14, 2012, 7:32 PM A class action lawsuit charges St. Jude Medical (STJ) with misrepresenting facts around the company's Riata and Riata ST defibrillator leads (discontinued last year). Plaintiffs say protruding wires on those and other products caused short circuits that the company failed to disclose. Comment! [Healthcare]
- Tuesday, June 12, 2012, 12:44 PM St. Jude Medical (STJ -5.5%) shares plunge suddenly on a report that the company's Durata defribilator is linked to a cable defect. STJ has had a similar problem with its Riata lead, which is no longer on the market; the company has said Durata leads, which it still sells, don't have the problem because they use a different type of insulation material. Comment! [Healthcare, On the Move]
-
The Wall Street Transcript
Growth Catalysts Despite Many Headwinds in Med Tech; Analyst Discusses $ABMD, $BSX, $EW, $MDT, $STJ, $SYK, $ZMH - http://su.pr/2BOPoN - View all 0 replies
-
John Cofran
rolled my $CMI Jan 110 covered call position up to 140 and my STJ Jan 42.50 covered calls up to Jan 45's - View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
Alan Brochstein
$STJ getting upgrades today - stock up despite slightly weak guidance. Looks like the downtrend has ended - View all 0 replies
-
- View all 8 replies
-
-
Jeremy Johnson: STJ is not expensive, but it is getting close to fair value. Fair value stocks are still good to own... fair equity return is 8% a year.
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
LATEST REPLIES